USFDA Audit Process in Pharmaceuticals
The USFDA audit process, also referred to as an FDA inspection, is a structured, risk-based, on-site examination conducted to ensure that facilities manufacturing FDA-regulated products comply with applicable federal laws and Current Good Manufacturing Practices (CGMP).
For pharmaceutical companies, biologics manufacturers, medical device firms, and API manufacturers, understanding the FDA inspection process is critical. A well-managed inspection not only ensures regulatory compliance but also builds trust with global regulators and customers.
What Is the USFDA Audit?
The USFDA audit is a systematic evaluation of manufacturing facilities that produce products regulated by the U.S. Food and Drug Administration. The primary objective of the inspection is to verify compliance with CGMP requirements.
FDA inspections are risk-based, meaning facilities with higher risk profiles—such as sterile manufacturing sites, firms with past violations, or those producing critical drugs are inspected more frequently.
Key Stages of the USFDA Audit
The FDA inspection process follows a sequence of events described below.
1. Pre-Inspection / Notification Stage
In most routine inspections, the FDA provides advance notification to the facility. This notification allows the company to make necessary arrangements and ensure the availability of key personnel, documents, and areas for inspection.
However, it is important to note that:
For-cause inspections may occur without prior notice
Surprise inspections are legally permitted by the FDA
Companies must always be in a state of inspection readiness
The companies must adopt continuous CGMP compliance, not just preparing for audits when notified.
2. Opening Meeting and FDA Form 482
The inspection officially begins with an opening meeting between FDA investigators and site management.
During this meeting:
FDA investigators present their official credentials
FDA Form 482 (Notice of Inspection) is issued
The scope and purpose of the inspection are explained
The Form 482 legally authorizes FDA investigators to inspect the facility. From this point onward, the inspection is considered active.
3. Facility Walkthrough and On-Site Inspection
Following the opening meeting, investigators conduct a physical walkthrough of the facility. This is one of the most critical stages of the USFDA audit process.
Typical areas inspected include:
Manufacturing and production areas
Quality Control laboratories
Warehouses and storage areas
Cleanrooms and controlled environments
Utility systems such as water, HVAC, and compressed air
Investigators observe:
Actual practices versus written procedures
Personnel hygiene and gowning practices
Equipment condition and cleanliness
Material flow and segregation
Any mismatch between documented procedures and real-time practices can raise compliance concerns.
4. Document Review and Staff Interviews
After or during the walkthrough, FDA investigators review of documentation and directly interact with personnel.
Common documents reviewed include:
Standard Operating Procedures (SOPs)
Batch manufacturing and testing records
Training records
Equipment calibration and maintenance records
Validation and qualification documents
Deviation, CAPA, and change control records
Facility layouts
Investigators may interview:
QA and QC staff
Production operators
Supervisors and department heads
Employees are expected to answer questions clearly based on documented procedures and actual practices.
5. Closing Meeting and FDA Form 483
At the conclusion of the inspection, the FDA conducts a closing meeting with site management.
During this meeting:
Investigators summarize their observations
Any significant CGMP deficiencies are discussed
FDA Form 483 (Inspectional Observations) may be issued
A Form 483 lists observed conditions by investigator’s judgment that may constitute violations of FDA regulations. Receiving a Form 483 does not automatically mean regulatory action, but it requires immediate attention and corrective measures.
6. Post-Inspection Response and Reporting
After receiving a Form 483, the inspected firm is must submit a written response, usually within 15 working days.
The response should include:
Acknowledgment of observations
Root cause analysis
Corrective and Preventive Actions (CAPA)
Implementation timelines and evidence
The FDA reviews the response and determines the final inspection classification, which may include:
No Action Indicated (NAI)
Voluntary Action Indicated (VAI)
Official Action Indicated (OAI)
The quality of the post-inspection response plays a major role in the FDA’s final decision.
Types of FDA Inspections
The USFDA conducts different types of inspections based on regulatory needs.
1. Surveillance Inspections
Surveillance inspections are routine inspections that FDA conducts to monitor ongoing compliance with CGMP requirements. These inspections help the FDA assess whether a facility continues to operate in a state of control.
2. Pre-Approval Inspections (PAI)
Pre-Approval Inspections are conducted as part of the review of a new drug application (NDA), ANDA, or biologics application.
The FDA verifies:
Manufacturing capability
Consistency between application data and on-site practices
Approval of the product is closely linked to the outcome of this inspection.
3. For-Cause Inspections
For-cause inspections are targeted inspections triggered by specific concerns, such as:
Product complaints
Recalls
Adverse events
Previous serious violations
These inspections are often more focused and intense than routine inspections.